CNS Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
CNS Pharmaceuticals, Inc. carries a market capitalization of 3.01M, placing it among publicly traded companies globally.
| Market Cap | 3.01M |
| Enterprise Value | N/A |
Share Statistics
CNS Pharmaceuticals, Inc. currently has 811,449.00 shares outstanding.
| Shares Outstanding | 811,449.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.01 |
| P/TBV Ratio | 18.09 |
| P/FCF Ratio | -0.08 |
| P/OCF Ratio | -0.08 |
Financial Position
CNS Pharmaceuticals, Inc. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.89 |
| Quick Ratio | 0.64 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,098.22 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -179.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CNS Pharmaceuticals, Inc.'s stock has declined approximately -56.76568% over the past 52 weeks. The 50-day moving average sits at 3.81, while the 200-day moving average is 5.68.
| Beta (5Y) | N/A |
| 52-Week Price Change | -56.76568% |
| 50-Day Moving Average | 3.81 |
| 200-Day Moving Average | 5.68 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.62M, while operating income came in at -16.62M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -16.62M |
| Pretax Income | -16.49M |
| Net Income | -16.49M |
| EBITDA | -16.62M |
| EBIT | -16.62M |
| Earnings Per Share (EPS) | -30.81 |
Balance Sheet
Total book value stands at -105.21M, with working capital of -504,148.00 providing operational flexibility.
| Cash & Cash Equivalents | 2.95M |
| Total Debt | N/A |
| Net Debt | -2.72M |
| Equity (Book Value) | -105.21M |
| Book Value Per Share | -196.64 |
| Working Capital | -504,148.00 |
Cash Flow
CNS Pharmaceuticals, Inc. produced -15.22M in operating cash flow over the past twelve months. After subtracting -6,179.00 in capital expenditures, free cash flow totaled -15.22M - equivalent to -28.45 per share.
| Operating Cash Flow | -15.22M |
| Capital Expenditures | -6,179.00 |
| Free Cash Flow | -15.22M |
| FCF Per Share | -28.45 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -402.37 |
| FCF Yield | -1,189.54 |
Stock Splits
CNS Pharmaceuticals, Inc.'s most recent stock split took place on July 22, 2025 with a 12:1 split ratio.
| Last Split Date | 7/22/2025 |
| Split Ratio | 12:1 |
Scores
CNS Pharmaceuticals, Inc. posts an Altman Z-Score of -43.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -43.41 |